RNA Therapies for sHTG and FCS

CE / CME

Meeting the Challenge: Transforming Patient Care in sHTG and FCS With Novel RNA-Based Therapies

Physician Assistants/Physician Associates: 1.25 AAPA Category 1 CME credits

Nurse Practitioners/Nurses: 1.25 Nursing contact hours

Physicians: maximum of 1.25 AMA PRA Category 1 Credits

Released: April 21, 2025

Expiration: April 20, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Which of the following best describes the pathophysiology of FCS?

2.

The PALISADE trial evaluated the efficacy of plozasiran in patients with FCS. Based on the trial results, compared with placebo, plozasiran demonstrated a significant reduction in:

3.

A 35-yr-old woman with FCS presents with persistent sHTG (>1500 mg/dL) despite strict adherence to a very low–fat diet. She has a history of recurrent pancreatitis and reports significant challenges in maintaining triglyceride control. Which of the following therapies would be the most appropriate to help lower her triglyceride levels and reduce her risk of pancreatitis?